FBN’s Liz MacDonald on the S&P 500 sector winners and losers.
Earnings HQ: FBN’s Lori Rothman breaks down Pfizer’s second-quarter earnings report.
Ralph Acampora of Altraira Wealth Management on where to invest in today’s markets.
FiREapps CEO Wolfgang Koester on how currency swings are impacting international trading and Wall Street.
FBN’s Nicole Petallides on the Dow, S&P 500 and Nasdaq highs.
FBN’s Liz MacDonald on GM’s additional recalls and the details of the victim compensation.
Tanium Board member Steven Sinofsky on the company.
Former White House economic adviser Todd Buchholz and Axel Merk of Merk Investments discuss wage inflation.
FBN’s Charles Payne, retail analyst Hitha Prabhakar, Penn Financial Group founder Matt McCall, FBN’s Tracy Byrnes and FOXBusiness.com reporter Kate Rogers on whether a tax holiday would benefit the economy.
Rehmann Financial Principal Joe Heider on the health-care stocks to watch.
Money Map Press’ Keith Fitz-Gerald, FBN’s Nicole Petallides and Liz MacDonald on the markets, Apple, James Bullard, the economy, job market and Merck .
FBN’s Liz MacDonald with an update on stocks.
Wells Fargo analyst John Baumgartner on Tyson’s bid for Hillshire.
Apple sells a record 10 million iPhone 6 and 6 Plus
Meridian Equity Partners Jonathan Corpina, Hennessy Funds Portfolio Manager Neil Hennessy, Ira Epstein of The Lynn Group and FBN contributor Phil Flynn discuss which S&P stocks are seeing green.
Progressive columnist Rick Ungar, The Wall Street Journal Columnist Veronica Dagher and FBN’s David Asman on reports Germany’s Angela Merkel is trying to keep energy out of sanctions against Russia.
Hedgeye Risk Management CEO Keith McCullough on investing in IPOs and growth.
FBN’s Charles Payne, retail analyst Hitha Prabhakar, Penn Financial Group founder Matt McCall, Divine Capital CEO Dani Hughes and FOXBusiness.com reporter Kate Rogers offer tips for doing investment research.
FBN’s Maria Bartiromo breaks down what you need to know in business news today.
Earnings HQ: FBN’s Lori Rothman breaks down Merck ’s second-quarter earnings report.